Propel Bio Management, LLC
Los Angeles, CA · CIK 1969764 · 13F filing filed 2024-08-12
SEC-registered investment adviser since 2022 · limited liability company
- Assets managed$247.5m
- Staff7 · 6 in investment roles
- Main clients (by assets)Private funds 70%, Mutual funds and ETFs 30%
- Private funds4 (1 hedge) · $172.2m gross assets
- Form ADV · 2026-03-23SEC adviser record
- Legal entityPropel Bio Management LLC (US)
- Kindhedge funds, venture
- Others nearbyLos Angeles, CA
As an employer
- Offices in1 country
- Private fundshedge 1, venture capital 1, other private 2
$154.2m
reported value
-10.3% vs Q1 2024
24positions
83.3%in top 10
4 new
4 added
0 reduced
8 sold out
vs Q1 2024
This report includes the holdings of 1 other manager that shares the investment decisions:
- Simplify Asset Management Inc. – files its own report too; $94.9m of shares are in both
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| APPLIED THERAPEUTICS INC APLT | $30.7m19.89% | Added +456.0k |
| PLAINS GP HLDGS L P PAGP | $25.8m16.75% | New |
| TSCAN THERAPEUTICS INC TCRX | $12.2m7.92% | Unchanged |
| MADRIGAL PHARMACEUTICALS INC MDGL | $12.1m7.82% | Unchanged |
| ACHIEVE LIFE SCIENCES INC ACHV | $11.5m7.48% | Unchanged |
| PHATHOM PHARMACEUTICALS INC PHAT | $9.0m5.81% | Unchanged |
| AKERO THERAPEUTICS INC AKRO | $7.7m4.99% | Unchanged |
| AVIDITY BIOSCIENCES INC RNA | $7.3m4.73% | Unchanged |
| ARDELYX INC ARDX | $6.9m4.44% | Added +330.4k |
| ABEONA THERAPEUTICS INC ABEO | $5.3m3.43% | New |
| FULCRUM THERAPEUTICS INC FULC | $4.7m3.02% | Unchanged |
| ATHIRA PHARMA INC COM | $4.0m2.57% | Unchanged |
| TELESAT CORP TSAT | $3.3m2.16% | Added +75.0k |
| VERRICA PHARMACEUTICALS INC COM | $3.1m2.01% | New |
| KURA ONCOLOGY INC KURA | $2.7m1.74% | Unchanged |
| EIGER BIOPHARMACEUTICALS INC CLDN | $1.9m1.20% | Unchanged |
| SYNDAX PHARMACEUTICALS INC SNDX | $1.7m1.11% | Unchanged |
| KYMERA THERAPEUTICS INC KYMR | $1.7m1.09% | Unchanged |
| KAYNE ANDERSON ENERGY INFRST KYN | $1.5m0.99% | Unchanged |
| TREVI THERAPEUTICS INC TRVI | $774.8k0.50% | Unchanged |
| FIDELITY INV MMTRSY 1 680 COMM | $317.0k0.21% | Added +105.5k |
| CYBIN INC COM | $230.3k0.15% | Unchanged |
| MAAT PHARMA SACA COMM | $9.8k0.01% | New |
| CHINOOK THERAPEUTICS XXX COM | $9.8k0.01% | Unchanged |
Sold out since Q1 2024
| Security | Value then |
|---|---|
| SIMPLIFY EXCHANGE TRADED FUN HIGH | $28.0m1.5m shares |
| DAY ONE BIOPHARMACEUTICALS I | $4.5m270.7k shares |
| ISHARES TR MBB | $2.1m22.4k shares |
| MIRUM PHARMACEUTICALS INC MIRM | $1.8m70.0k shares |
| MARINUS PHARMACEUTICALS INC MRNS | $1.6m180.1k shares |
| SUTRO BIOPHARMA INC | $1.1m195.0k shares |
| X4 PHARMACEUTICALS INC | $743.6k535.0k shares |
| ISHARES TR LQD | $485.3k4.5k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| MILESTONE PHARMACEUTICALS IN MIST · 13G · filed 2025-12-23 | 9.9%≈ $11.9m |